Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

SB939 is a pan-inhibitor of histone deacetylases (HDACs; Kis = 16-247 nM for HDAC1-11).1 It inhibits proliferation of A2780, COLO 205, HCT116, and PC3 cancer cells (IC50s = 0.48, 0.56, 0.48, and 0.34 µM, respectively). SB939 (50 and 100 mg/kg) reduces tumor growth and increases survival in an HCT116 mouse xenograft model. It synergizes with pacritinib (Item No. 16709) to decrease the number of metastases in a MOLM-13 mouse xenograft model when administered at a dose of 75 mg/kg.2
WARNING This product is not for human or veterinary use.
1. Discovery of (2E)-
2. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J. 2(5), 1-10 (2012).